Pharmaceuticals company Bajaj Healthcare announced Q1FY26 results Revenue from operations stood at Rs 1,488.4 million, up 12.5% year-on-year EBITDA was Rs 253.9 million, largely flat with a 0.1% YoY increase EBITDA margin stood at 17.0%, compared to 19.1% in Q1FY25 PAT from continuing operations came in at Rs 121.7 million, rising 51.7% YoY PAT margin from continuing operations improved to 8.1% from 6.0% Loss from discontinued operations narrowed to Rs 3.4 million from Rs 8.9 million Total profit for the period stood at Rs 118.3 million, up 65.9% YoY Overall profit margin rose to 7.9% from 5.4% in Q1FY25 Commenting on the Results, Anil Jain – Managing Director said, “Q1 FY26 marks a strong and promising start to the new fiscal year for Bajaj Healthcare, despite a challenging pricing environment in certain segments. Revenue from operations rose 12.5% year-onyear to Rs 1,488.4 million, while PAT grew by 66% to Rs 118.3 million, reflecting improved profitability and sharper execution across business segments. EBITDA remained steady at Rs 253.9 million, with margins improving sequentially to 17.0% from 15.1%, reflecting better product mix and improved operating leverage, even amidst input cost pressures. Segment-wise, our API export business delivered standout growth of 68.4% YoY, supported by growing demand in regulated markets and the ramp-up of commercial CDMO supplies. Formulations saw 41.1% year-on-year growth, led by deeper market penetration and new strategic partnerships. Due to pricing headwinds in the domestic API segment, the company has strategically realigned its portfolio towards value-added exports and differentiated molecules to reinforce growth and profitability. ….We are pleased to report that during the quarter, we received three new CEP approvals and one ASMF approval from European regulatory authority, further strengthening our position in regulated EU/UK markets. Following product approvals, validation batch supplies have commenced for a few molecules under CDMO agreements. In parallel, five DMFs were filed with the UK MHRA to enable future commercial supply and regulatory compliance. To date, we have filed a total of nine CEPs, out of which seven have been approved. Furthermore, four additional CEP filings are in process. Our CNS portfolio continues to evolve with notable regulatory developments. Cenobamate has received a positive recommendation from the Subject Expert Committee (SEC) and is currently awaiting final DCGI approval to initiate Phase III trials. For Magtein®, validation batches are underway, with commercial launch targeted in Q3. These developments mark important steps toward expanding our product pipeline. Backward integration continues to be a cornerstone of our strategy, especially in supporting scale-up across CDMO and formulation segment. Export contribution rose to 35% of total revenue, up from 23% last year, reflecting stronger API demand and deeper access to global markets. We remain firmly on course to build a value-driven, innovation-led growth engine across APIs, formulations, and CDMO.” Result PDF
Pharmaceuticals company Bajaj Healthcare announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations increased by 15.4%, rising to Rs 1,544.7 million from Rs 1,339.0 million. Gross Profit rose significantly by 30.8% to Rs 740.8 million from Rs 566.5 million. EBITDA grew by 12.6% to Rs 253.3 million from Rs 224.9 million. EBITDA Margin (%) declined slightly to 15.1% from 16.0%. Profit for the period turned positive at Rs 111.8 million, compared to a loss of Rs (299.2) million in Q4 FY24. FY25 Financial Highlights: Revenue from Operations increased by 14.6% to Rs 5,426.0 million from Rs 4,734.2 million. Gross Profit improved by 21.2% to Rs 2,755.6 million from Rs 2,273.3 million. EBITDA grew by 19.9% to Rs 1,018.3 million from Rs 849.5 million. EBITDA Margin (%) rose slightly to 18.1% from 17.6%. Profit for the period turned around to a profit of Rs 395.0 million, compared to a loss of Rs (837.9) million in FY24. Commenting on the Results, Anil Jain – Managing Director said, “FY25 has been a transformational year for Bajaj Healthcare. We have delivered a strong financial turnaround and regained profitability, reflecting our commitment to operational discipline and long-term value creation. We closed the year with a net profit of Rs 395 million, a significant swing from losses in the previous year. Gross margin expanded to 49%, supported by a more favorable product mix. EBITDA grew by 20% year-on-year, outpacing revenue growth and reflecting the benefits of improved operating leverage and cost efficiencies. Despite headwinds in the API segment across the industry, I am proud to share that we achieved approximately 8% year-on-year revenue growth in our overall API business in FY25. Our Formulations segment also delivered exceptional year-on-year revenue growth of 69% during the same period. These gains reflect the strategic realignment of our portfolio and improved utilization across key facilities. A key development was the acquisition of Genrx Pharmaceuticals Pvt. Ltd., possession of which was taken in April 2025, significantly enhancing our manufacturing infrastructure and enabling future portfolio expansion. From a product innovation standpoint, we continue to build a differentiated pipeline in CNS and wellness categories. The launch of Pimavanserin and the progress of Cenobamate toward final regulatory approval reflect our ability to deliver niche and high-impact therapies in India. We also made significant headway in expanding our presence in regulated international markets. With new CDMO partnerships and regulatory clearances now in place, we are on track to become a credible outsourcing partner for global pharma. Our exports currently account for 24% of total revenue, and with these new partnerships, we aim to substantially increase our export share going forward. We enter FY26 with renewed momentum, a differentiated pipeline, and scalable capacity across APIs, formulations, and CDMO. We are committed to building Bajaj Healthcare into a trusted global pharmaceutical partner through innovation, regulatory strength, and operational excellence.” Result PDF
Pharmaceuticals company Bajaj Healthcare announced Q3FY25 results Revenue: Rs 1,227.9 million compared to Rs 1,085.7 million during Q3FY24, change 13.1%. EBITDA: Rs 240.1 million compared to Rs 203.3 million during Q3FY24, change 18.1%. EBITDA margin: 19.6% for Q3FY25. PAT: Rs 117.2 million compared to Rs -219.6 million during Q3FY24, change 153.4%. PAT margin: 9.5% for Q3FY25. Anil Jain, Managing Director, said: “We are pleased to report yet another strong quarter of growth and profitability. Our PAT from continuing operations surged 171% YoY, driven by our relentless focus on operational excellence and cost efficiencies. At the same time, we remain committed to monetizing assets from discontinued operations, ensuring optimal capital allocation towards debt repayment and minimizing associated losses. Notably, our formulations segment saw a significant growth, with an impressive 58% YoY increase for the quarter. This rise in formulations revenue highlights the strength of our manufacturing expertise, as we continue to expand our portfolio and enhance our capabilities to meet market demand across key therapeutic areas. Our opium processing segment saw a 32% YoY growth and we remain optimistic about the long-term prospects of the alkaloid processing segment. Beyond financials, we reached significant milestones strengthening our market position. A key achievement was receiving approval from the Drug Controller General of India (DCGI) to manufacture both the API and formulation of Pimavanserin, solidifying our foothold in the central nervous system (CNS) segment. Pimavanserin, marketed globally as NUPLAZID®, has already gained significant traction in the US, and with Acadia Pharmaceuticals projecting combined net sales of over USD 1 billion in 2025 for NUPLAZID® and DAYBUE, we see a tremendous opportunity ahead. We are proud to expand our CDMO pipeline with a new contract for 15 APIs with UK/EU-based companies, reinforcing our global presence and expertise in cost-effective synthesis. This follows our earlier contract for 15 molecules this year. Additionally, the approval of our Gujarat API manufacturing site by the TGA, Australia, alongside USFDA and EU certifications, enables direct supplies to Australia and New Zealand, unlocking new global partnership opportunities. Looking ahead, we remain confident in our growth, driven by operational excellence, strategic partnerships, and innovation, as we work towards becoming a trusted global pharmaceutical partner.” Result PDF
Pharmaceuticals company Bajaj Healthcare announced Q2FY25 results Revenue from Operations: Rs 1,330.9 million compared to Rs 1,012.1 million, change 31.5% YoY. EBITDA: Rs 245.2 million compared to Rs 189.5 million, change 29.4% YoY. EBITDA Margin: 18.4% for Q2FY25. PAT: Rs 94.6 million compared to Rs -34.6 million. PAT Margin: 7.1% for Q2FY25. Anil Jain, Managing Director, said: “I am delighted to present the impressive results of our second quarter for FY25. Our revenue from operations surged by approximately 32% YoY led by robust performance across all segments this coupled with expansion in our margins resulted in a 90% year-onyear increase in our bottom line from our continuing operations. We continue to undertake all efforts to sell the assets from the discontinued operations and to use the proceeds for further debt repayment and minimize the losses from the discontinued operations. We have materially repaid our borrowings to the tune of Rs 1,500 million and this has further strengthened our financial position. Contribution from our API and Formulation segments rose, with both registering strong growth at 19% and 28%, respectively. The domestic demand has remained quite encouraging and has been a source of strength even as export markets are still largely wrestling sticky inflation and elevated freights. Another key highlight was the exceptional performance of our Opium Processing business, which grew multi-fold year-on-year. The segment has quickly become a meaningful growth driver for our overall business. We are focused on expanding capacity to meet increasing government requirements and sustain its high growth trajectory going forward. Our new development and supply agreement with a European partner for an Active Pharmaceutical Ingredient (API) underscores our commitment to maintaining the highest standards of quality, as evidenced by our adherence to Good Manufacturing Practices. This also presents us with a fascinating opportunity to showcase our development capabilities and further strengthen our CDMO business. It pleases me to report that we successfully completed an approximately Rs 2,050 million fund raise denoting the strong investor belief in our company’s abilities and our upcoming growth journey. We are now firmly on the path to maintaining profitability on an overall basis and look to carry forward this positive momentum from our recent performances.” Result PDF